APA

Lin W., Chen F. & Han C. (20120321). Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. : Annals of surgical oncology.

Chicago

Lin Wea-Lung, Chen Fong-Lin and Han Chih-Ping. 20120321. Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. : Annals of surgical oncology.

Harvard

Lin W., Chen F. and Han C. (20120321). Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. : Annals of surgical oncology.

MLA

Lin Wea-Lung, Chen Fong-Lin and Han Chih-Ping. Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. : Annals of surgical oncology. 20120321.